SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

UBS Maintains Neutral on Amedisys, Lowers Price Target to $190

UBS maintains Amedisys (NASDAQ:AMED) with a Neutral and lowers the price target from $208 to $190.

Benzinga · 05/11/2020 14:17

UBS maintains Amedisys (NASDAQ:AMED) with a Neutral and lowers the price target from $208 to $190.